# TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary

> **NCT00296816** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 132 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab (Avastin®)
- **DRUG:** Docetaxel (Taxotere®)
- **DRUG:** Oxaliplatin (Eloxatin®)

## Key facts

- **NCT ID:** NCT00296816
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2012-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00296816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00296816, "TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00296816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*